

Molecular Partners - Pioneers of DARPins




DARPin therapeutics are a new class of custom-built drugs with the potential to offer unique solutions for defined medical problems not readily addressable by other drug modalities

Pioneering new therapeutics for patients

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering DARPin therapeutics for patients. Founded in 2004, we are a team of approximately 150 dedicated and passionate colleagues with operations in Switzerland and the U.S. Through our leadership, together with partners, we have:

- Developed 8 clinical-stage DARPin candidates
- Treated >2500 patients globally
- Demonstrated clinical value of DARPin therapeutics across several therapeutic areas
- Reached late-stage clinical development, including registrational stage



DARPin therapeutics – a new drug class

DARPin (Designed Ankyrin Repeat Protein) therapeutics are a new class of custom-built drugs based on natural binding proteins with the potential to overcome several limitations of current protein-based therapeutics. DARPin therapeutics can be tailored to specific disease biology by leveraging key advantages of DARPins:

- Small size with very flexible and stable architecture
- High affinity and specificity to targets
- Broad target range
- Modular design: radically simple (single DARPin for one target) or multispecific (>5 targets possible)
- Simple high-yield manufacturing




Bright future for DARPins

There is great need to deliver disease-specific solutions for diverse conditions. Through our 20 years of leadership and experience with DARPins, we have advanced the power and versatility of DARPin therapeutics for the benefit of patients. As our understanding of the mechanisms of various diseases deepens, the opportunity for DARPin therapeutics is greater than ever.

Extending the boundaries of targeted cancer therapies with DARPin therapeutics

Radio-DARPin therapeutics




MP0712 – TARGETED ALPHA RADIATION FOR SCLC PATIENTS

MP0712 is a Radio-DARPin therapeutic that delivers the potent radioactive payload lead-212 precisely to tumors through a custom-engineered DLL3-targeting DARPin. DLL3 is a validated target expressed in >85% small cell lung cancer (SCLC) patients. MP0712 is co-developed with our strategic partner Orano Med and a Phase 1/2a study in the US is planned to start by end 2025.

RADIO-DARPINS – EXPANDING THE TARGET SPACE

Our Radio-DARPins are designed as ideal vectors for targeted delivery of therapeutic radionuclides to a broad range of targets expressed in cancer patients. We design our candidates to minimize kidney retention, a historic challenge for the approach, while increasing tumor uptake through precise control of how long the candidates stay in the body. We have demonstrated favorable biodistribution and tumor shrinkage in pre-clinical models.

Next-generation immune cell engagers



MP0533 – TARGETED T CELL ENGAGER FOR AML PATIENTS

MP0533 is a novel, tetra-specific T cell engager designed for thorough destruction of acute myeloid leukemia (AML) cells – blasts and also leukemic stem cells known to drive relapse. MP0533 targets three antigens preferentially co-expressed on AML cells and leverages an avidity effect to strongly favor binding and killing of AML cells, while minimizing damage to healthy cells. MP0533 is in a Phase 1/2a multi-center study in Europe.

SWITCH-DARPINS – CONDITIONAL T CELL ACTIVATION

We design our Switch-DARPins as next-generation immune cell engagers with increased safety and potency by providing a logic-gated “on/off” function (the “Switch”) to multi-specific DARPin molecules. Switch-DARPins allow conditional, tumor-localized immune activation only in the presence of defined targets. We have shown pre-clinically the feasibility of conditional T cell activation with potent co-stimulation in solid tumors while sparing healthy tissues.

